September 24th, 2019. On Thursday, September 18th, the EC-funded project RECOPHARMA held its mid-term review meeting in Lund, Sweden.
The purpose of the meeting was to present of the main objectives and general overview of the project and the results achieved so far in training, networking, implementation of secondments and the future exploitation of the results.
The partnership was highly commended by the EU Project Officer (Dr. S. Kiokias) for the successful implementation, coordination and management of the project to date. The Project Officer emphasised the importance of the partner’s commitment on the implementation of the RISE initiative, while acknowledging the challenges of balancing scientific achievements while pursuing a post-doc qualification, so that the project will be, ‘Meaningful scientifically while creating long-term sustainable partnerships’.
In this sense, the main presented outcomes included the finally selected cytostatic drugs being targeted by the project, the summary of studied candidates as microporous cryogels and nanoparticles with their corresponding adsorption performances, the manufactured reactors for the pilot plant and the plethora of outreach, dissemination and communication actions performed so far. Now, the partnership address during the coming months the final validation of the methodology for the monitoring of selected cytostatic drugs in real samples as well as the selection of the best candidates to be implemented within different designs of reactors at the pilot plant, once tested their viability for a reagentless thermodesorption process.
Fure initiatives including participation in Erasmus plus and ITN Programs, besides other possible bilateral collaborations, were included in the agenda to extend the present project activities.
Image caption: WP5 Leader Leonardo Piccinetti (EfB) presenting WP5 results
Image caption: Recopharma Consortium
#sciencecafe; #recopharma
______________________________________________
About the RECOPHARMA Project
The RECOPHARMA Project emerged from a need to develop an effective treatment to recover Recalcitrant Cytostatic Drugs (CDs) through the sequential integration of the potential offered by technologies such as Molecularly Imprinted Polymers (MIPs), Reagentless Thermosorption (RTS), Nanocomposites Functional Materials (NFMs) and Advanced Oxidation Processes (AOP).
The RECOPHARMA Project, formed by 8 partners (see partners section), is a Research and Innovation Staff Exchange action, fostering intersectorial mobility between Europe and Cuba.
Initiated on 01/01/2018, during the 48 months of the project 107 exchanges will be carried out (199 P M). This project is co-financed by the Marie Skłodowska-Curie (MSCA) Research and Innovation Staff Exchange (RISE) of the European Research Framework Horizon2020 (with a budget of 895.000€).Co-funded by the Horizon 2020 Framework Programme of the European Union – Marie Skłodowska-Curie actions
For information about the RECOPHARMA H2020 project:
twitter: @recopharma_info
For information, contact:
Coordinator: Prof. Manuel Valiente
Universitat Autònoma de Barcelona,
Science Faculty. Building – Chemistry Department
08193, Bellaterra
Barcelona (Spain)
Tel: (+34) 93 581 49 38
